As a part of the deal, Apeiron will offer in vitro and in vivo pharmacology knowledge to the research while Evotec will contribute medicinal chemistry in addition to chemical proteomics.
Evotec chief operating officer Dr Mario Polywka said, "The collaboration highlights the strength of Evotec’s phenotypic screening capabilities to identify novel mechanisms and hits in important therapeutic areas."
The outcome of a phenotypic high throughput screen earlier commissioned by Apeiron to Evotec is the leading cause for the collaboration.
Apeiron chief executive officer Dr Hans Loibner said ‘We were excited about the outcome of the primary screen and look forward to refining the hit compounds in this collaboration applying our immunological know-how."
Financial details of the deal are kept confidential.